
Viridian Therapeutics Inc
NASDAQ:VRDN

Operating Margin
Viridian Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
![]() |
Viridian Therapeutics Inc
NASDAQ:VRDN
|
1.2B USD |
-111 591%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
324.6B USD |
30%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
146.5B USD |
25%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
131.7B USD |
38%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114B USD |
38%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
116.6B AUD |
26%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.4B USD |
29%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41B USD |
-5%
|
Viridian Therapeutics Inc
Glance View
In the bustling frontier of biotechnology, Viridian Therapeutics Inc. emerges as a dynamic player, carving a niche within the field of precision medicine. Founded with the mission to revolutionize treatment regimens for serious diseases, Viridian channels its expertise into developing innovative therapies for rare and underserved conditions. The company primarily focuses on advancing its pipeline of monoclonal antibodies to combat and manage thyroid eye disease (TED), a rare autoimmune disorder. By leveraging cutting-edge research and development, Viridian harnesses its scientific prowess to translate complex biological insights into promising therapeutic candidates. The meticulous process involves extensive clinical trials and regulatory navigation, ensuring that only robustly tested solutions reach the medical community. Viridian's business model hinges on strategic collaborations, licensing agreements, and scientific innovation. It navigates the intricate landscape of biotechnology by forging alliances with research institutions and industry leaders to bolster its R&D capabilities. These collaborations not only expedite the drug development process but also provide opportunities for licensing and milestone payments, supplementing early-stage revenue. Ultimately, the true engine of Viridian’s financial performance lies in successfully bringing its therapeutic offerings to the market. In this competitive sphere, generating revenue manifests through the commercialization of their approved treatments, and as these therapies gain traction in medical circles, the company anticipates a revenue stream through product sales and partnerships, cementing its position as a leader in targeted therapies for rare conditions.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Viridian Therapeutics Inc's most recent financial statements, the company has Operating Margin of -111 591.1%.